Clinical Trials Browser

bintrafusp alfa protein, human × Breast × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03620201 2024-10-22

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Phase 1 Completed

20 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04756505 2023-12-27

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT04489940 2023-04-10

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Phase 2 Terminated

11 enrolled 9 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1 Terminated

38 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03524170 2022-03-07

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 1 Completed

24 enrolled

Breast

Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1 Terminated

1 enrolled 10 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)